

Aerocrine

Aerocrine AB:s extraordinary general meeting 2010

An extraordinary general meeting was held in Aerocrine AB (publ) on Thursday 21 October 2010 in Solna

The meeting resolved to appoint Scott Beardsley as new member of the board. In accordance with what has previously been communicated, Lars Gatenbeck resigned as board member in connection with the extraordinary general meeting.

For complete information regarding the proposal resolved upon by the meeting, please visit www.aerocrine.se where documentation related to the meeting is available for download.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007..

Aerocrine may be is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 08:00 am on 22 October 2010.